



EVALUATING A NOVEL HOST-IMMUNE BASED ASSAY FOR DISTINGUISHING BACTERIAL FROM VARIOUS VIRAL INFECTIONS IN FEBRILE CHILDREN

Background


1. A novel host-immune signature



2. A new IVD assay for distinguishing between bacterial and viral infections



3. Assay validated in several clinical studies





4. Study goal

To evaluate the assay's ability to assign correct infection classification (viral or bacterial) in children infected with ten different types of viral strains as well as in bacterially infected children

'Curiosity' study - Oved et al. *PLOS ONE* 2015; Eden et al. *Journal of Infection* 2016.
'Opportunity' study – van-Houten et al *Lancet Infectious Diseases* 2016.

Design and Results



- ImmunoXpert™ correctly classified 90% of bacterial cases and 91% of viral cases, when compared to the expert panel diagnoses (13% of patients had an equivocal response).
- Assay classified all coronavirus, bocavirus, human metapneumovirus, and enterovirus cases correctly.
- In the case of adenovirus, which is known to trigger a bacterial-like inflammatory host response, the assay correctly classified 83% of the patients. In comparison, CRP (cut-off: 40 mg/l) correctly classified only 42% of adenovirus infections.
- The assay may aid clinicians in determining infection etiology in febrile children. Importantly, it may assist in distinguishing between adenovirus and bacterial infections, which can be associated with similar clinical presentation.